Evidence map›Paper›PMID 34970434›Full record

ArticleInternational journal of inflammation2021

Protective Effect of Bergapten against Human Erythrocyte Hemolysis and Protein Denaturation

Douglas Bosco Aidoo, Daniels Konja, Isaac Tabiri Henneh, Martins Ekor

Open access · goldAbstract read
In one paragraph

Article in International journal of inflammation, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 22 papers.

0numbers the graph read from it
0cells of the map it votes in
22citing papers in PubMed
8.4field-weighted citation impact, top 2% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

22 citing papers in PubMed, 60 citations in OpenAlex.

  1. Article
  2. Article
  3. Article
  4. Pharmacological Assessment ofFood science & nutrition · 2026
    Article
  5. Article
  6. Article
  7. Anti-Inflammatory Activity ofPharmaceuticals (Basel, Switzerland) · 2026
    Article
  8. Article
  9. Article
  10. Article
  11. Review
  12. Investigating a newBiotechnology reports (Amsterdam, Netherlands) · 2025
    Article
  13. Influence ofBiology · 2025
    Article
  14. Article
  15. Article
  16. Article
  17. Article
  18. Article
  19. Article
  20. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

4 authors at 2 institutions in 1 country.

Douglas Bosco AidooDepartment of Pharmacology, Faculty of Pharmacy and Pharmaceutical Sciences, College of Health Sciences, Kwame Nkrumah University of Science & Technology, Kumasi, Ghana.ORCID https://orcid.org/0000-0002-8361-9006
Daniels KonjaDepartment of Biomedical Sciences, School of Allied Health Sciences, University of Cape Coast, Cape Coast, Ghana.ORCID https://orcid.org/0000-0003-1515-8938
Isaac Tabiri HennehDepartment of Pharmacotherapeutics and Pharmacy Practice, School of Pharmacy and Pharmaceutical Sciences, College of Health and Allied Sciences, University of Cape Coast, Cape Coast, Ghana.ORCID https://orcid.org/0000-0002-6830-0283
Martins EkorDepartment of Pharmacology, School of Medical Sciences, College of Health and Allied Sciences, University of Cape Coast, Cape Coast, Ghana.ORCID https://orcid.org/0000-0002-4683-0988
University of Cape Coast · GHKwame Nkrumah University of Science and Technology · GH

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Bergapten, a furocoumarin found in many medicinal plants, is used for the management of various conditions. The present

Identifiers

PMID34970434
PMCPMC8714387
OpenAlexW4200570011

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.